Seeking Alpha Your next question comes from the line of Sumant Kulkarni with Bank of America. Sumant S. Kulkarni - BofA Merrill Lynch, Research Division. The first one is on the base business. How has competition been so far, on Fenofibrate and how do you expect ... and more »
MarketWatch (press release) These decreases were partially offset by products sold in the first quarter of 2013 that were not sold in the first quarter of 2012, the largest of which was fenofibrate , the generic equivalent of TriCor(R). -- European revenues of $873 million, an ... and more »
Sacramento Bee This improvement was achieved in spite of a decrease in overall sales primarily from a reduction in partnered generic products which are low margin (e.g. ...
Wall Street Journal (press release) UCERIS(TM) (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID(R) ( omeprazole /sodium bicarbonate) for the treatment of certain upper gastrointestinal disorders ... and more »
